Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Up 349.0% in February

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 22,000 shares, an increase of 349.0% from the February 13th total of 4,900 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 63,700 shares, the days-to-cover ratio is presently 0.3 days.

Estrella Immunopharma Trading Up 5.3 %

Shares of NASDAQ:ESLA traded up $0.05 during mid-day trading on Thursday, reaching $1.02. The company had a trading volume of 22,685 shares, compared to its average volume of 77,283. The firm has a market cap of $36.90 million, a price-to-earnings ratio of -3.92 and a beta of 0.40. The company’s 50-day moving average price is $1.14 and its 200-day moving average price is $1.07. Estrella Immunopharma has a one year low of $0.63 and a one year high of $3.23.

Institutional Investors Weigh In On Estrella Immunopharma

A hedge fund recently raised its stake in Estrella Immunopharma stock. Geode Capital Management LLC increased its stake in Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 22.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 93,418 shares of the company’s stock after purchasing an additional 16,862 shares during the quarter. Geode Capital Management LLC owned approximately 0.26% of Estrella Immunopharma worth $106,000 at the end of the most recent quarter. 0.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital initiated coverage on shares of Estrella Immunopharma in a research report on Tuesday, February 18th. They set a “buy” rating and a $16.00 target price on the stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.